Loading…
Loading…
PNT (POINT Biopharma Global Inc.) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
PNT does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for PNT and 80,000+ other tickers.
See exactly how PNT's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for PNT and 80,000+ other tickers.
POINT Biopharma Global Inc. functions as a radiopharmaceutical company dedicated to the advancement and commercialization of specialized radioligand therapies designed to combat various cancerous conditions. Its two primary investigational treatments, both currently in Phase III clinical trials, are PNT2002, a radioligand engineered to target prostate-specific membrane antigen (PSMA) for addressing metastatic castration-resistant prostate cancer, and PNT2003, a somatostatin-targeted radioligand being evaluated for the treatment of neuroendocrine tumors. Beyond these late-stage programs, the…
IRDM targets the emerging Assured PNT market with its new ASIC, gaining adoption across 150+ organizations and opening recurring revenue opportunities.
Ultra-compact chip delivers trusted positioning, navigation, and timing resilience amid rising spoofing and jamming threats MCLEAN, Va., July 14, 2026 /PRNewswire/ -- Iridium Communications Inc. (Nasdaq: IRDM), a leading provider of global voice, data, and positioning, navigation, and timing (PNT) satellite services, today announced the commercial availability of the Iridium PNT ASIC, a first-to-market chip designed to help protect GPS- and GNSS-dependent devices from jamming, spoofing, and other growing threats.
Mlink chipsets expand the ecosystem for Iridium's standards-based NB-IoT and D2D connectivity MCLEAN, Va., June 24, 2026 /PRNewswire/ -- Iridium Communications Inc. (Nasdaq: IRDM), a leading provider of global voice, data, and positioning, navigation, and timing (PNT) satellite services, today announced that Mlink Technology Inc. (Mlink), a leading fabless semiconductor company specializing in IoT and satellite communication chipsets, has begun live, on-air testing of its MS150-IR IoT-NTN chipset using Iridium NTN Direct℠.
The Iridium 9604 Module and Development Kit streamline global IoT development with integrated satellite, cellular, and GNSS connectivity MCLEAN, Va., June 23, 2026 /PRNewswire/ -- Iridium Communications Inc. (Nasdaq: IRDM), a leading provider of global voice, data, and positioning, navigation, and timing (PNT) satellite services, today announced commercial availability of the Iridium® 9604 module and Development Kit, giving developers, OEMs, and solution providers a faster path to build and scale connected IoT solutions worldwide.
RESTON, Va.--(BUSINESS WIRE)--NextNav Inc. (NASDAQ: NN) (“NextNav or the “Company”) a leader in next-generation 3D positioning, navigation, and timing (PNT) solutions, today announced that it has delivered a notice of redemption for all of its outstanding 5.00% Senior Secured Convertible Notes due 2028 (the “Notes”). The Notes will be redeemed on June 25, 2026 (the “Redemption Date”), at a price equal to 100% of their principal amounts, plus accrued but unpaid interest (the “Redemption Price”),.